CYP 1.89% 27.0¢ cynata therapeutics limited

Stuart Robert's Pitt Street Report, page-2

  1. 6,922 Posts.
    lightbulb Created with Sketch. 1282
    This bit is interesting:

    "Cynata is currently good value, in our opinion. We value Cynata at
    $2.18 per share base case and $4.21 per share optimistic case, using
    a probability-weighted DCF method. Should the GvHD study show the
    clinical utility of the Cymerus technology, we see Cynata being rerated."


    These guys would have to pop up as a major shareholder of CYP in the coming weeks, given the current price and their valuation?

    Seems crazy that they wouldn't take their own advice.




    I'll wait for the ASX announcement of a new major shareholder................waiting.............I'll come back and revisit...........

 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
27.0¢
Change
0.005(1.89%)
Mkt cap ! $48.50M
Open High Low Value Volume
27.0¢ 27.0¢ 27.0¢ $4 13

Buyers (Bids)

No. Vol. Price($)
1 18895 26.5¢
 

Sellers (Offers)

Price($) Vol. No.
28.5¢ 5700 1
View Market Depth
Last trade - 13.43pm 05/07/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.